

# Michele Simonato

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4112797/publications.pdf>

Version: 2024-02-01

115  
papers

4,693  
citations

87888

38  
h-index

110387

64  
g-index

121  
all docs

121  
docs citations

121  
times ranked

5595  
citing authors

#	ARTICLE	IF	CITATIONS
1	Advances in the development of biomarkers for epilepsy. <i>Lancet Neurology</i> , The, 2016, 15, 843-856.	10.2	283
2	Identification of new epilepsy treatments: Issues in preclinical methodology. <i>Epilepsia</i> , 2012, 53, 571-582.	5.1	219
3	Progress in gene therapy for neurological disorders. <i>Nature Reviews Neurology</i> , 2013, 9, 277-291.	10.1	202
4	Systems genetics identifies Sestrin 3 as a regulator of a proconvulsant gene network in human epileptic hippocampus. <i>Nature Communications</i> , 2015, 6, 6031.	12.8	158
5	Localized delivery of fibroblast growth factor <sup>2</sup> and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 7191-7196.	7.1	134
6	Gene Therapy Tools for Brain Diseases. <i>Frontiers in Pharmacology</i> , 2019, 10, 724.	3.5	131
7	Brain-Derived Neurotrophic Factor mRNA and Protein Are Targeted to Discrete Dendritic Laminas by Events That Trigger Epileptogenesis. <i>Journal of Neuroscience</i> , 2004, 24, 6842-6852.	3.6	130
8	Blockade of Nociceptin/Orphanin FQ Transmission Attenuates Symptoms and Neurodegeneration Associated with Parkinson's Disease. <i>Journal of Neuroscience</i> , 2005, 25, 9591-9601.	3.6	116
9	Are the neurotrophic factors a suitable therapeutic target for the prevention of epileptogenesis?. <i>Epilepsia</i> , 2010, 51, 48-51.	5.1	106
10	Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures. <i>Journal of Neuroinflammation</i> , 2010, 7, 81.	7.2	105
11	Differential expression of immediate early genes in the hippocampus in the kindling model of epilepsy. <i>Molecular Brain Research</i> , 1991, 11, 115-124.	2.3	103
12	The challenge and promise of anti-epileptic therapy development in animal models. <i>Lancet Neurology</i> , The, 2014, 13, 949-960.	10.2	101
13	MicroRNA profiles in hippocampal granule cells and plasma of rats with pilocarpine-induced epilepsy â€“ comparison with human epileptic samples. <i>Scientific Reports</i> , 2015, 5, 14143.	3.3	101
14	Opportunities for improving animal welfare in rodent models of epilepsy and seizures. <i>Journal of Neuroscience Methods</i> , 2016, 260, 2-25.	2.5	93
15	Angels and demons: neurotrophic factors and epilepsy. <i>Trends in Pharmacological Sciences</i> , 2006, 27, 631-638.	8.7	86
16	Finding a better drug for epilepsy: Antiepileptogenesis targets. <i>Epilepsia</i> , 2012, 53, 1868-1876.	5.1	82
17	DYNORPHIN AND EPILEPSY. <i>Progress in Neurobiology</i> , 1996, 50, 557-583.	5.7	79
18	Antinociceptive Activity of the N-Methyl-d-aspartate Receptor Antagonist N-(2-Indanyl)-glycinamide Hydrochloride (CHF3381) in Experimental Models of Inflammatory and Neuropathic Pain. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 306, 804-814.	2.5	77

#	ARTICLE	IF	CITATIONS
19	Acetylcholine Content in Rat Brain Is Elevated by Status Epilepticus Induced by Lithium and Pilocarpine. <i>Journal of Neurochemistry</i> , 1987, 49, 944-951.	3.9	72
20	Finding a better drug for epilepsy: Preclinical screening strategies and experimental trial design. <i>Epilepsia</i> , 2012, 53, 1860-1867.	5.1	69
21	Functional antagonism between nociceptin/orphanin FQ (N/OFQ) and corticotropin-releasing factor (CRF) in the rat brain: evidence for involvement of the bed nucleus of the stria terminalis. <i>Psychopharmacology</i> , 2008, 196, 523-531.	3.1	64
22	Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus. <i>Epilepsia</i> , 2011, 52, 572-578.	5.1	63
23	Gene transfer into neurones for the molecular analysis of behaviour: focus on herpes simplex vectors. <i>Trends in Neurosciences</i> , 2000, 23, 183-190.	8.6	61
24	GABA <sub>A</sub> -current rundown of temporal lobe epilepsy is associated with repetitive activation of GABA <sub>A</sub> α <sub>1</sub> receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 20944-20948.	7.1	60
25	Seizure-Suppressant and Neuroprotective Effects of Encapsulated BDNF-Producing Cells in a Rat Model of Temporal Lobe Epilepsy. <i>Molecular Therapy - Methods and Clinical Development</i> , 2018, 9, 211-224.	4.1	59
26	On the Role of Somatostatin in Seizure Control: Clues from the Hippocampus. <i>Reviews in the Neurosciences</i> , 2003, 14, 285-301.	2.9	57
27	Identification of clinically relevant biomarkers of epileptogenesis – a strategic roadmap. <i>Nature Reviews Neurology</i> , 2021, 17, 231-242.	10.1	54
28	What Is the Biological Significance of BDNF mRNA Targeting in the Dendrites?: Clues From Epilepsy and Cortical Development. <i>Molecular Neurobiology</i> , 2006, 33, 017-032.	4.0	50
29	Autoradiographic analysis of rat brain kinin B1 and B2 receptors: Normal distribution and alterations induced by epilepsy. <i>Journal of Comparative Neurology</i> , 2003, 461, 506-519.	1.6	49
30	Enhancement of GABA <sub>A</sub> -current run-down in the hippocampus occurs at the first spontaneous seizure in a model of temporal lobe epilepsy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 3180-3185.	7.1	49
31	Unverricht-Lundborg disease. <i>Epileptic Disorders</i> , 2016, 18, 28-37.	1.3	46
32	A pathogenetic hypothesis of Unverricht-Lundborg disease onset and progression. <i>Neurobiology of Disease</i> , 2007, 25, 675-685.	4.4	45
33	Standardization procedure for plasma biomarker analysis in rat models of epileptogenesis: Focus on circulating microRNAs. <i>Epilepsia</i> , 2017, 58, 2013-2024.	5.1	45
34	Impairment of GABA release in the hippocampus at the time of the first spontaneous seizure in the pilocarpine model of temporal lobe epilepsy. <i>Experimental Neurology</i> , 2014, 257, 39-49.	4.1	44
35	Loss of cortical GABA terminals in Unverricht-Lundborg disease. <i>Neurobiology of Disease</i> , 2012, 47, 216-224.	4.4	42
36	Gene therapy for epilepsy. <i>Epilepsy and Behavior</i> , 2014, 38, 125-130.	1.7	42

#	ARTICLE	IF	CITATIONS
37	Adenosine receptor antagonists alter the stability of human epileptic GABA <sub>A</sub> receptors. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 15118-15123.	7.1	41
38	Evaluation of cell damage in organotypic hippocampal slice culture from adult mouse: A potential model system to study neuroprotection. Brain Research, 2011, 1385, 68-76.	2.2	41
39	Antipsychotic drugs counteract autophagy and mitophagy in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	40
40	Nociceptin/Orphanin FQ Receptor Agonists Attenuate L-DOPA-Induced Dyskinesias. Journal of Neuroscience, 2012, 32, 16106-16119.	3.6	39
41	Brain Interstitial Nociceptin/Orphanin FQ Levels are Elevated in Parkinson's Disease. Movement Disorders, 2010, 25, 1723-1732.	3.9	37
42	Increased excitability in tat-transgenic mice: Role of tat in HIV-related neurological disorders. Neurobiology of Disease, 2013, 55, 110-119.	4.4	37
43	Prostaglandin F <sub>2</sub> ± Is Required for NMDA Receptor-Mediated Induction of c-fos mRNA in Dentate Gyrus Neurons. Journal of Neuroscience, 1997, 17, 117-124.	3.6	36
44	Anaphylactic shock and acute pulmonary edema after a single oral dose of acetazolamide. American Journal of Emergency Medicine, 2002, 20, 371-372.	1.6	36
45	Involvement of the Neuropeptide Nociceptin/Orphanin FQ in Kainate Seizures. Journal of Neuroscience, 2002, 22, 10030-10038.	3.6	36
46	Increased extracellular levels of glutamate in the hippocampus of chronically epileptic rats. Neuroscience, 2015, 301, 246-253.	2.3	36
47	Identification of miRNAs Differentially Expressed in Human Epilepsy with or without Granule Cell Pathology. PLoS ONE, 2014, 9, e105521.	2.5	36
48	Common data elements and data management: Remedy to cure underpowered preclinical studies. Epilepsy Research, 2017, 129, 87-90.	1.6	35
49	FGF-2 Overexpression Increases Excitability and Seizure Susceptibility but Decreases Seizure-Induced Cell Loss. Journal of Neuroscience, 2008, 28, 13112-13124.	3.6	33
50	Different patterns of induction of FGF-2, FGF-1 and BDNF mRNAs during kindling epileptogenesis in the rat. European Journal of Neuroscience, 1998, 10, 955-963.	2.6	32
51	Pro-nociceptin/orphanin FQ and NOP receptor mRNA levels in the forebrain of food deprived rats. Brain Research, 2002, 957, 354-361.	2.2	32
52	Discovery and validation of blood microRNA's as molecular biomarkers of epilepsy: Ways to close current knowledge gaps. Epilepsia Open, 2018, 3, 427-436.	2.4	32
53	Long-Term, Targeted Delivery of GDNF from Encapsulated Cells Is Neuroprotective and Reduces Seizures in the Pilocarpine Model of Epilepsy. Journal of Neuroscience, 2019, 39, 2144-2156.	3.6	29
54	Joint AES/ILAE translational workshop to optimize preclinical epilepsy research. Epilepsia, 2013, 54, 1-2.	5.1	28

#	ARTICLE	IF	CITATIONS
55	Adenosine A1 receptors in the rat brain in the kindling model of epilepsy. <i>European Journal of Pharmacology</i> , 1994, 265, 121-124.	3.5	27
56	Circadian differences in the individual sensitivity to opiate overdose. <i>Critical Care Medicine</i> , 2001, 29, 96-101.	0.9	27
57	Kainate seizures increase nociceptin/orphanin FQ release in the rat hippocampus and thalamus: a microdialysis study. <i>Journal of Neurochemistry</i> , 2004, 91, 30-37.	3.9	27
58	Engineered HSV vector achieves safe long-term transgene expression in the central nervous system. <i>Scientific Reports</i> , 2017, 7, 1507.	3.3	27
59	Dose- and time-dependent hippocampal cholinergic lesions induced by ethylcholine mustard aziridinium ion: Effects of nerve growth factor, GM1 ganglioside, and vitamin E. <i>Neurochemical Research</i> , 1988, 13, 685-692.	3.3	25
60	Effects of [Nphe <sup>1</sup> , Arg <sup>14</sup> , Lys <sup>15</sup> ] N/OFQ-NH <sub>2</sub> (UFP-101), a potent NOP receptor antagonist, on molecular, cellular and behavioural alterations associated with chronic mild stress. <i>Journal of Psychopharmacology</i> , 2017, 31, 691-703.	4.0	25
61	Alterations in Seizure Susceptibility and in Seizure-induced Plasticity after Pharmacologic and Genetic Manipulation of the Fibroblast Growth Factor-2 System. <i>Epilepsia</i> , 2005, 46, 52-58.	5.1	23
62	Issues for new antiepilepsy drug development. <i>Current Opinion in Neurology</i> , 2013, 26, 195-200.	3.6	23
63	NPY and Gene Therapy for Epilepsy: How, When,... and Y. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 608001.	2.9	23
64	Meta-Analysis of MicroRNAs Dysregulated in the Hippocampal Dentate Gyrus of Animal Models of Epilepsy. <i>ENeuro</i> , 2017, 4, ENEURO.0152-17.2017.	1.9	23
65	Somatostatin Release in the Hippocampus in the Kindling Model of Epilepsy. <i>Journal of Neurochemistry</i> , 2002, 74, 2497-2503.	3.9	22
66	Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist. <i>NeuroReport</i> , 2002, 13, 2071-2074.	1.2	21
67	Changes in the sensitivity of GABAA current rundown to drug treatments in a model of temporal lobe epilepsy. <i>Frontiers in Cellular Neuroscience</i> , 2013, 7, 108.	3.7	21
68	BODIPY <sup>®</sup> -conjugated neuropeptide Y ligands: new fluorescent tools to tag Y1, Y2, Y4 and Y5 receptor subtypes. <i>British Journal of Pharmacology</i> , 2005, 146, 1069-1081.	5.4	20
69	Proposal for a phase II multicenter trial model for preclinical new antiepilepsy therapy development. <i>Epilepsia</i> , 2013, 54, 70-74.	5.1	19
70	Delayed epileptogenesis in nociceptin/orphanin FQ-deficient mice. <i>NeuroReport</i> , 2003, 14, 825-827.	1.2	17
71	Synthesis and anticonvulsant activity of a class of 2-amino 3-hydroxypropanamide and 2-aminoacetamide derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 3263-3274.	3.0	17
72	Bradykinin B2 receptors increase hippocampal excitability and susceptibility to seizures in mice. <i>Neuroscience</i> , 2013, 248, 392-402.	2.3	17

#	ARTICLE	IF	CITATIONS
73	Advancing research toward faster diagnosis, better treatment, and end of stigma in epilepsy. <i>Epilepsia</i> , 2019, 60, 1281-1292.	5.1	17
74	<i>SREBP2</i> gene therapy targeting striatal astrocytes ameliorates Huntington's disease phenotypes. <i>Brain</i> , 2021, 144, 3175-3190.	7.6	17
75	Different Patterns of Induction of Fibroblast Growth Factor-2 and Brain-Derived Neurotrophic Factor Messenger RNAs During Kindling Epileptogenesis, and Development of a Herpes Simplex Vector for Fibroblast Growth Factor-2 Gene Transfer in Vivo. <i>Epilepsia</i> , 2000, 41, S122-S126.	5.1	16
76	The biocompatibility of materials used in printed circuit board technologies with respect to primary neuronal and K562 cells. <i>Biomaterials</i> , 2010, 31, 1045-1054.	11.4	16
77	Limbic seizures increase pronociceptin mRNA levels in the thalamic reticular nucleus. <i>NeuroReport</i> , 1999, 10, 541-546.	1.2	15
78	Implication of fibroblast growth factors in epileptogenesis-associated circuit rearrangements. <i>Frontiers in Cellular Neuroscience</i> , 2013, 7, 152.	3.7	15
79	Harmonization in preclinical epilepsy research: A joint AES/ILAE translational initiative. <i>Epilepsia</i> , 2017, 58, 7-9.	5.1	15
80	A Pathogenetic Hypothesis of Temporal Lobe Epilepsy. <i>Pharmacological Research</i> , 1993, 27, 216-226.	7.1	14
81	5-Hydroxytryptamine-mediated effects of nicotine on endogenous GABA efflux from guinea pig cortical slices. <i>British Journal of Pharmacology</i> , 1995, 116, 2724-2728.	5.4	14
82	Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 6, 79-90.	4.1	14
83	eIF4B phosphorylation at Ser504 links synaptic activity with protein translation in physiology and pathology. <i>Scientific Reports</i> , 2017, 7, 10563.	3.3	14
84	WONOE appraisal: New genetic approaches to study epilepsy. <i>Epilepsia</i> , 2014, 55, 1170-1186.	5.1	13
85	WONOE appraisal: Development of epilepsy biomarkers—What we can learn from our patients?. <i>Epilepsia</i> , 2017, 58, 951-961.	5.1	13
86	Epilepsy an Update on Disease Mechanisms: The Potential Role of MicroRNAs. <i>Frontiers in Neurology</i> , 2018, 9, 176.	2.4	13
87	Cellular Antisilencing Elements Support Transgene Expression from Herpes Simplex Virus Vectors in the Absence of Immediate Early Gene Expression. <i>Journal of Virology</i> , 2018, 92, .	3.4	12
88	2017 WONOE appraisal: Studying epilepsy as a network disease using systems biology approaches. <i>Epilepsia</i> , 2019, 60, 1045-1053.	5.1	12
89	Unilateral ex vivo gene therapy by GDNF in epileptic rats. <i>Gene Therapy</i> , 2019, 26, 65-74.	4.5	12
90	Is autopsy tissue a valid control for epilepsy surgery tissue in microRNA studies?. <i>Epilepsia Open</i> , 2017, 2, 90-95.	2.4	11

#	ARTICLE	IF	CITATIONS
91	A Matter of Genes: The Hurdles of Gene Therapy for Epilepsy. <i>Epilepsy Currents</i> , 2019, 19, 38-43.	0.8	11
92	Biotin deficiency facilitates kindling hyperexcitability in rats. <i>NeuroReport</i> , 1996, 7, 1745-1748.	1.2	9
93	Neurotrophic factors and status epilepticus. <i>Epilepsia</i> , 2018, 59, 87-91.	5.1	9
94	New Tools for Epilepsy Therapy. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 147.	3.7	9
95	Lack of excitatory amino acid-induced effects on calcium fluxes measured with $^{45}\text{Ca}^{2+}$ in rat cerebral cortex synaptosomes. <i>Neurochemical Research</i> , 1989, 14, 677-682.	3.3	8
96	Changes in NPY-mediated modulation of hippocampal $[^3\text{H}]\text{D}$ -aspartate outflow in the kindling model of epilepsy. <i>Synapse</i> , 2003, 49, 116-124.	1.2	8
97	Silencing Status Epilepticus-Induced BDNF Expression with Herpes Simplex Virus Type-1 Based Amplicon Vectors. <i>PLoS ONE</i> , 2016, 11, e0150995.	2.5	8
98	Identification and characterization of outcome measures reported in animal models of epilepsy: Protocol for a systematic review of the literature—A TASK 2 report of the AES/ILAE Translational Task Force of the ILAE. <i>Epilepsia</i> , 2017, 58, 68-77.	5.1	8
99	Time- and Region-Specific Variations in Somatostatin Release Following Amygdala Kindling in the Rat. <i>Journal of Neurochemistry</i> , 1998, 70, 252-259.	3.9	7
100	Mechanisms of action of CHF3381 in the forebrain. <i>British Journal of Pharmacology</i> , 2003, 139, 1333-1341.	5.4	7
101	Changes in $[^3\text{H}]\text{UK14304}$ binding to $\text{AD}$ receptors in morphine-dependent guinea pigs. <i>British Journal of Pharmacology</i> , 1995, 116, 3125-3132.	5.4	5
102	From fix to fit into the autaptic human brains. <i>European Journal of Histochemistry</i> , 2018, 62, .	1.5	5
103	Implication of sestrin3 in epilepsy and its comorbidities. <i>Brain Communications</i> , 2021, 3, fcaa130.	3.3	5
104	Gene networks and microRNAs: Promises and challenges for treating epilepsies and their comorbidities. <i>Epilepsy and Behavior</i> , 2021, 121, 106488.	1.7	4
105	Absence of RNA-binding protein FXR2P prevents prolonged phase of kainate-induced seizures. <i>EMBO Reports</i> , 2021, 22, e51404.	4.5	4
106	Kindled seizure-evoked somatostatin release in the hippocampus. <i>NeuroReport</i> , 2000, 11, 3209-3212.	1.2	3
107	Bystander Effect on Brain Tissue of Mesoangioblasts Producing Neurotrophins. <i>Cell Transplantation</i> , 2012, 21, 1613-1627.	2.5	3
108	Improvement of HSV-1 based amplicon vectors for a safe and long-lasting gene therapy in non-replicating cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 399-412.	4.1	2

#	ARTICLE	IF	CITATIONS
109	Anti-epileptogenic effect of NRP2945 in the pilocarpine model of temporal lobe epilepsy. European Journal of Pharmacology, 2021, 901, 174068.	3.5	2
110	Personalized Needles for Microinjections in the Rodent Brain. Journal of Visualized Experiments, 2018, , .	0.3	1
111	Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats. Journal of Visualized Experiments, 2018, , .	0.3	1
112	Meeting report: EpiXchange II brings together European epilepsy research projects to discuss latest advances. Epilepsy Research, 2021, 178, 106811.	1.6	1
113	Gene Therapy for Neurological Diseases. , 2015, , 129-146.		0
114	Cell Therapy for Epilepsy. Molecular and Translational Medicine, 2017, , 85-97.	0.4	0
115	I06â€¦SREBP2 delivery to striatal astrocytes normalizes transcription of cholesterol biosynthesis genes and ameliorates pathological features in huntingtonâ€™s disease. , 2021, , .		0